Go Pro
→ They didn't warn anyone in 1971. This time someone is warning you. (From Reagan Gold Group) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Boundless Bio, Inc. stock logo
BOLD
Boundless Bio
$2.83
+1.8%		$2.31
$0.96
▼
$2.97
$63.13M-0.08264,691 shs108,951 shs
HIND
Vyome
$2.18
+0.9%		$2.17
$1.75
▼
$16.00
$15.16M1.489,293 shs6,140 shs
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
$1.09
+21.1%		$1.03
$0.56
▼
$2.98
$93.07M1.525.18 million shs12.17 million shs
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
$1.52
+0.7%		$1.56
$1.34
▼
$3.20
$79.24M0.04109,191 shs65,020 shs
7 Stocks to Buy And Hold Forever Cover
7 Stocks to Buy And Hold Forever

Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Boundless Bio, Inc. stock logo
BOLD
Boundless Bio
0.00%-2.11%+13.01%+86.58%+136.60%
HIND
Vyome
-2.70%+1.89%-0.92%+14.29%+215,999,900.00%
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
+16.90%+33.59%-22.41%-30.76%-47.05%
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
+0.33%-1.63%-4.43%-3.82%-43.45%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Boundless Bio, Inc. stock logo
BOLD
Boundless Bio
$2.83
+1.8%		$2.31
$0.96
▼
$2.97
$63.13M-0.08264,691 shs108,951 shs
HIND
Vyome
$2.18
+0.9%		$2.17
$1.75
▼
$16.00
$15.16M1.489,293 shs6,140 shs
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
$1.09
+21.1%		$1.03
$0.56
▼
$2.98
$93.07M1.525.18 million shs12.17 million shs
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
$1.52
+0.7%		$1.56
$1.34
▼
$3.20
$79.24M0.04109,191 shs65,020 shs
7 Stocks to Buy And Hold Forever Cover
7 Stocks to Buy And Hold Forever

Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Boundless Bio, Inc. stock logo
BOLD
Boundless Bio
0.00%-2.11%+13.01%+86.58%+136.60%
HIND
Vyome
-2.70%+1.89%-0.92%+14.29%+215,999,900.00%
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
+16.90%+33.59%-22.41%-30.76%-47.05%
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
+0.33%-1.63%-4.43%-3.82%-43.45%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Boundless Bio, Inc. stock logo
BOLD
Boundless Bio
1.00
SellN/AN/A
HIND
Vyome
2.40
Hold$15.00588.07% Upside
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
2.75
Moderate Buy$3.17190.52% Upside
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
2.40
Hold$5.67272.81% Upside

Current Analyst Ratings Breakdown

Latest HIND, INO, BOLD, and OKYO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/13/2026
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
8/13/2026
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingNeutral
8/13/2026
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
Jefferies Financial Group Inc. logo
Jefferies Financial Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold ➝ Positive$1.80 ➝ $3.00
8/12/2026
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold ➝ Strong-Buy
8/3/2026
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
Piper Sandler logo
Piper Sandler
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOverweight$4.00
7/29/2026
Boundless Bio, Inc. stock logo
BOLD
Boundless Bio
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
7/29/2026
HIND
Vyome
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
7/29/2026
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
7/17/2026
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
7/13/2026
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$7.00 ➝ $5.00
7/1/2026
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
(Data available from 8/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Boundless Bio, Inc. stock logo
BOLD
Boundless Bio
N/AN/AN/AN/A$2.90 per shareN/A
HIND
Vyome
$320K47.82N/AN/A$1.04 per share2.10
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
$60K1,878.43N/AN/A$0.04 per share27.25
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
N/AN/AN/AN/A$0.30 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Boundless Bio, Inc. stock logo
BOLD
Boundless Bio
-$58.20M-$2.86N/AN/AN/AN/A-70.89%-47.37%N/A
HIND
Vyome
-$10.26M-$12.27N/AN/AN/A-3,024.84%-197.33%-138.14%N/A
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
-$84.95M-$1.45N/AN/AN/AN/A-669.94%-73.97%N/A
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
-$8.95MN/AN/AN/AN/AN/AN/AN/AN/A

Latest HIND, INO, BOLD, and OKYO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/12/2026Q2 2026
HIND
Vyome
N/A-$0.10N/A-$0.10N/A$0.27 million
8/12/2026Q2 2026
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
-$0.2167-$0.07+$0.1467-$0.07$0.53 millionN/A
8/7/2026Q2 2026
Boundless Bio, Inc. stock logo
BOLD
Boundless Bio
N/A-$1.06N/A-$1.06N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Boundless Bio, Inc. stock logo
BOLD
Boundless Bio
N/AN/AN/AN/AN/A
HIND
Vyome
N/AN/AN/AN/AN/A
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
N/AN/AN/AN/AN/A
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Boundless Bio, Inc. stock logo
BOLD
Boundless Bio
N/A
9.48
9.87
HIND
Vyome
N/A
4.37
4.27
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
N/A
1.00
1.04
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
N/A
2.43
2.43

Institutional Ownership

CompanyInstitutional Ownership
Boundless Bio, Inc. stock logo
BOLD
Boundless Bio
N/A
HIND
Vyome
22.06%
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
26.79%
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
2.97%

Insider Ownership

CompanyInsider Ownership
Boundless Bio, Inc. stock logo
BOLD
Boundless Bio
23.10%
HIND
Vyome
33.00%
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
1.70%
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
40.46%
CompanyEmployeesShares OutstandingFree FloatOptionable
Boundless Bio, Inc. stock logo
BOLD
Boundless Bio
6422.75 million17.49 millionNo Data
HIND
Vyome
507.02 million4.70 millionN/A
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
320103.40 million80.87 millionOptionable
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
752.48 million24.15 millionNot Optionable

Recent News About These Companies

Short Interest in OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Expands By 223.4%
August 13 at 1:19 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/short-interest-in-okyo-pharma-limited-sponsored-adr-nasdaqokyo-expands-by-2234-2026-08-13/
OKYO Pharma (OKYO) Expected to Post Quarterly Earnings on Monday
August 3, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/okyo-pharma-okyo-expected-to-post-quarterly-earnings-on-monday-2026-08-03/
OKYO Pharma Announces Purchase of Shares by Chief Scientific Officer
July 28, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/28/3334117/0/en/okyo-pharma-announces-purchase-of-shares-by-chief-scientific-officer.html
OKYO Pharma to Participate in the BTIG Biotechnology Conference 2026
July 27, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/27/3333362/0/en/okyo-pharma-to-participate-in-the-btig-biotechnology-conference-2026.html
OKYO Pharma outlines path to phase 3 NEPTUNE trial of urcosimod for neuropathic corneal pain
July 25, 2026  |  ophthalmologytimes.comO
OKYO Pharma Announces Purchase of Shares by Director
July 23, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/23/3332413/0/en/okyo-pharma-announces-purchase-of-shares-by-director.html
OKYO Pharma Announces Purchase of Shares by Chief Executive Officer
July 23, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/23/3331994/0/en/okyo-pharma-announces-purchase-of-shares-by-chief-executive-officer.html
OKYO Pharma Announces Purchase of Shares by Chairman
July 22, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/22/3331587/0/en/okyo-pharma-announces-purchase-of-shares-by-chairman.html
OKYO Pharma Announces Purchase of Shares by Chief Development Officer and Director
July 22, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/22/3331510/0/en/okyo-pharma-announces-purchase-of-shares-by-chief-development-officer-and-director.html
OKYO Pharma Announces Purchase of Shares by Chief Medical Officer
July 22, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/22/3331223/0/en/okyo-pharma-announces-purchase-of-shares-by-chief-medical-officer.html
OKYO Pharma to Present at the H.C. Wainwright 6th Annual Ophthalmology Virtual Conference
July 21, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/okyo-pharma-to-present-at-the-h-c-wainwright-6th-annual-ophthalmology-virtual-conference-1036345995
OKYO Pharma Announces Purchase of Shares by Chairman
July 21, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/21/3330300/0/en/okyo-pharma-announces-purchase-of-shares-by-chairman.html
Small caps: Replenish Nutrients, OKYO Pharma, EDM Resources
July 20, 2026  |  proactiveinvestors.comhttps://www.proactiveinvestors.com/companies/news/1095724?snapi
OKYO Pharma (NASDAQ:OKYO) Posts Earnings Results, Misses Estimates By $5.45 EPS
July 20, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/okyo-pharma-nasdaqokyo-posts-earnings-results-misses-estimates-by-545-eps-2026-07-20/
OKYO Pharma files annual report, highlights cash position and Phase 3 trial plans
July 20, 2026  |  proactiveinvestors.comhttps://www.proactiveinvestors.com/companies/news/1095701?snapi
OKYO Pharma Announces Filing of Annual Report with Strengthened Cash Position and Accelerated Phase 3 Plans
July 20, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/20/3329597/0/en/okyo-pharma-announces-filing-of-annual-report-with-strengthened-cash-position-and-accelerated-phase-3-plans.html
OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Receives Average Rating of "Hold" from Brokerages
July 20, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/okyo-pharma-limited-sponsored-adr-nasdaqokyo-receives-average-rating-of-hold-from-brokerages-2026-07-20/
OKYO Pharma to Highlight Neuropathic Corneal Pain Program at Piper Sandler Virtual Ophthalmology Symposium
July 14, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/OKYO/pressreleases/3181476/okyo-pharma-to-highlight-neuropathic-corneal-pain-program-at-piper-sandler-virtual-ophthalmology-symposium/
OKYO Pharma announces positive feedback from US FDA Type D Meeting and accelerates urcosimod into global phase 3 trial for NCP
July 11, 2026  |  pharmabiz.comP
OKYO Pharma advances toward Phase 3 FDA trial - ICYMI
July 11, 2026  |  proactiveinvestors.comhttps://www.proactiveinvestors.com/companies/news/1095285?snapi
Phase 3 trial to study urcosimod in neuropathic corneal pain
July 10, 2026  |  healio.comH

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
A wallet with cash, coffee, a sweater, sunglasses, and perfume on a counter beside a stainless steel refrigerator.
Confidence Is Back, But Earnings Show the Consumer Is Being Picky
By Jessica Mitacek | July 21, 2026
Palantir logo overlays a glowing global data network above a city skyline.
Why Palantir Investors Aren't Panicking While the Rest of AI Sells Off
By Chris Markoch | July 25, 2026
Robotics components including a sensor module, circuit board, motors, and a mechanical joint arranged on a table.
3 Picks-and-Shovels Stocks Powering the Humanoid Robotics Buildout
By Ryan Hasson | July 17, 2026
Illustration of a desk with miniature buildings, a monitor showing a portfolio dashboard, and fund brochures for growth, value, and industrial ETFs.
3 Value ETFs to Consider as Growth Stocks Lag Behind
By Nathan Reiff | July 28, 2026
Solventum logo with a green S icon on a light blue background featuring medical cross and network graphics.
Solventum Nears Inflection Point As It Begins to Unlock Value
By Thomas Hughes | August 7, 2026
Boundless Bio stock logo

Boundless Bio NASDAQ:BOLD

$2.83 +0.05 (+1.80%)
Closing price 04:00 PM Eastern
Extended Trading
$2.73 -0.10 (-3.50%)
As of 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.

Vyome NASDAQ:HIND

$2.18 +0.02 (+0.93%)
Closing price 04:00 PM Eastern
Extended Trading
$2.17 -0.01 (-0.32%)
As of 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

ReShape Lifesciences Inc., a medical device company, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company's product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; and ReShape Vest system, an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach to enable weight loss in obese and morbidly obese patients without cutting or permanently removing portions of the stomach, or bypassing any portion of the gastrointestinal tract. It also offers ReShapeCare virtual health coaching program, a virtual telehealth weight management program that supports healthy lifestyle changes for all medically managed weight-loss patients; and ReShape Diabetes Bloc-Stim Neuromodulation, a technology that is in preclinical development for the treatment of type 2 diabetes mellitus. In addition, the company provides Obalon Balloon System, a swallowable capsule used to track and display the location of the balloon during placement. The company was formerly known as EnteroMedics Inc. and changed its name to ReShape Lifesciences Inc. in 2017. ReShape Lifesciences Inc. was incorporated in 2002 and is headquartered in San Clemente, California.

Inovio Pharmaceuticals stock logo

Inovio Pharmaceuticals NASDAQ:INO

$1.09 +0.19 (+21.10%)
Closing price 04:00 PM Eastern
Extended Trading
$1.08 -0.02 (-1.38%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade dysplasia; INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial; INO-3112 for the treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma and is under Phase 2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under Phase 1b trial; INO-4800 for COVID-19 and is under Phase 3 trial; and INO-6160 for the treatment of human immunodeficiency virus and is under Phase 1 trial. Its partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency, The U.S. Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.

OKYO Pharma stock logo

OKYO Pharma NASDAQ:OKYO

$1.52 +0.01 (+0.66%)
Closing price 04:00 PM Eastern
Extended Trading
$1.53 +0.01 (+0.46%)
As of 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic chronic pain. The company was incorporated in 2007 and is headquartered in London, the United Kingdom.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas